KAM
BMRN icon

Krensavage Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Krensavage Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.6M Hold
524,786
– – 11.59% 4
2025
Q4 		$31.2M Buy
524,786
+119,336
+29% +$6.5M 11.02% 3
2025
Q3 		$22M Buy
+405,450
New +$23.2M 9.36% 4

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Krensavage Asset Management's BMRN Position: Q1 2026 in Review

Krensavage Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 524,786 shares worth $29.6M. The position accounts for 11.59% of the portfolio, ranked #4.

Krensavage Asset Management first reported a position in BMRN in Q3 2025 and has held it in 3 quarters since. The position peaked at $31.2M in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Krensavage Asset Management held 524,786 shares of BioMarin Pharmaceuticals worth $29.6M as of Q1 2026.
  • Krensavage Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
  • BioMarin Pharmaceuticals made up 11.59% of Krensavage Asset Management's portfolio in Q1 2026, its #4 holding.
  • Krensavage Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Krensavage Asset Management's BioMarin Pharmaceuticals position peaked at $31.2M in Q4 2025.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.